Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

270
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
270
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

281
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
281
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

334
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

300
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
300
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026
Same author

From Chatbot to Care Team: A Pilot Study of Generative Artificial Intelligence to Support Nurse-Pharmacist Collaboration and Patient Care in Telemedicine.

Journal of doctoral nursing practice·2026
Same author

Effect of Incentivizing Pediatric Studies on the Development of Pediatric-Friendly Formulations.

The AAPS journal·2026
Same author

PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development.

The AAPS journal·2026
Same author

Medical cannabis utilization in children - a study based on a nationwide cohort.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: Feb 15, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K

Obesity and Pediatric Drug Development.

Janelle D Vaughns1,2, Laurie S Conklin3, Ying Long4

  • 1Department of Anesthesiology, Pain, and Perioperative Medicine, Children's National Health System, Washington, DC, USA.

Journal of Clinical Pharmacology
|January 20, 2018
PubMed
Summary

Dosing guidelines for obese children are lacking, with limited data on how obesity affects drug safety and outcomes. Current drug development offers little guidance for safe pediatric obesity dosing.

Keywords:
drug developmentobesitypediatrics

More Related Videos

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

12.1K
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.9K

Related Experiment Videos

Last Updated: Feb 15, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K
Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

12.1K
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.9K

Area of Science:

  • Pharmacology
  • Pediatrics
  • Drug Development

Background:

  • Obesity in children presents challenges for safe and effective medication use due to a lack of specific dosing guidelines.
  • The impact of pediatric obesity on drug pharmacokinetics, safety, and clinical outcomes remains poorly understood.
  • Existing drug approval processes have not adequately addressed the unique needs of obese pediatric populations.

Purpose of the Study:

  • To evaluate the extent to which obesity is considered as a covariate in pediatric drug development.
  • To assess the availability of obesity-related dosing information in FDA drug reviews and labels for pediatric patients.
  • To identify gaps in current pediatric drug development concerning obese children.

Main Methods:

  • Reviewed pediatric medical and clinical pharmacology reviews from FDA Amendments Act (FDAAA) and FDA Safety and Innovation Act (FDASIA) submissions.
  • Analyzed FDA drug labels for any statements or keywords related to obesity in pediatric patients.
  • Quantified the number of drugs with obesity-related information in reviews and labels.

Main Results:

  • Forty-five drugs under FDAAA and 44 under FDASIA had obesity-related mentions in reviews or labels.
  • None of the 89 identified product labels provided specific dosing information for obese pediatric patients.
  • Only 4 labels mentioned the effect of body mass index on drug pharmacokinetics.

Conclusions:

  • There is a significant lack of available information to guide medication dosing in obese pediatric patients.
  • Regulators, clinicians, and the pharmaceutical industry must prioritize the inclusion of obese children in pediatric trials.
  • Future drug development needs to incorporate strategies for the safe and effective use of medications in the growing obese pediatric population.